PURPOSE: Lung cancer is the most common cancer worldwide, and is the leading cancer killer in both men and women in the United States. The overall five-year survival rate for lung cancer continues to remain poor <18 percent. Therefore, there is a need for predictive biomarker tests that can identify which therapies are most appropriate for individual patients and assess their prognostic outcome. A Blood/Serum-based proteomic test veristrat by mass spectrometry has been used to predict outcomes of patients with non-small cell lung cancer (NSCLC). The test classifies the patients in the poor group have worse outcomes after treatment as compared to patients with the good group which respond to treatment. Although this test was initially developed for patients with EGFR mutation, given that the majority of NSCLC cases do not harbor activating mutations in the EGFR gene, utility of this test must be assessed in all patients with NSCLC. In this study, we examined the predictive and prognostic values of blood-based proteomic test in assessing disease progression and recurrence in lung cancer.